Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Kidney J
Autores principales: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
CKD-Mdb
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://ncbi.nlm.nih.gov/pubmed/32082556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz034
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares